Dr. Kent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Bridge Plaza N
Sunovion Pharmaceuticals, Inc.
Fort Lee, NJ 07024Phone+1 508-787-4534
Education & Training
New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1991 - 1995
New York University School of MedicineClass of 1991
Certifications & Licensure
NJ State Medical License 2000 - 2021
Publications & Presentations
PubMed
- 24 citationsThe selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent
Translational Psychiatry. 2019-09-03 - 105 citationsMolecular targets in the treatment of anxietyJustine M. Kent, Sanjay J. Mathew, Jack M. Gorman
Biological Psychiatry. 2002-11-15 - 146 citationsClinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxietyJustine M. Kent, Jeremy D. Coplan, Jack M. Gorman
Biological Psychiatry. 1998-11-01
Press Mentions
Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in SchizophreniaDecember 12th, 2019
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with SchizophreniaSeptember 27th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
